Investors

Overview

Corporate Profile

Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
May 17, 2022

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference

Read More
May 10, 2022

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

Read More
May 05, 2022

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Read More
May 03, 2022

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

Read More
Apr 27, 2022

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 26, 2022

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Read More
Apr 25, 2022

Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 25, 2022

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 07, 2022

Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

Read More
Mar 15, 2022

Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Read More
Mar 10, 2022

Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference

Read More
Mar 08, 2022

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast

Read More
Feb 09, 2022

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

Read More
Jan 31, 2022

Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

Read More
Jan 31, 2022

Gamida Cell Provides Key Program Updates and 2022 Financial Guidance

Read More
Jan 19, 2022

Gamida Cell Provides Update on Omidubicel BLA Submission

Read More
Jan 07, 2022

Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Dec 13, 2021

Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting

Read More
Dec 11, 2021

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

Read More
Nov 16, 2021

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Read More